American Journal of Kidney Diseases
Volume 54, Issue 3 , Pages 478-489 , September 2009

Homocysteine as a Risk Factor for Cardiovascular Disease in Patients Treated by Dialysis: A Meta–analysis

  • Judith Heinz, MSc

      Affiliations

    • Institute of Clinical Chemistry and Pathobiochemistry, University Hospital Magdeburg, Magdeburg, Germany
    • Corresponding Author InformationAddress correspondence to Judith Heinz, Institute of Clinical Chemistry, Leipziger Str 44, D-39120 Magdeburg, Germany
    • ,
  • Siegfried Kropf, PhD

      Affiliations

    • Institute of Biometry and Medical Informatics, University Hospital Magdeburg, Magdeburg, Germany
    • ,
  • Claus Luley, MD

      Affiliations

    • Institute of Clinical Chemistry and Pathobiochemistry, University Hospital Magdeburg, Magdeburg, Germany
    • ,
  • Jutta Dierkes, PhD

      Affiliations

    • Institute of Clinical Chemistry and Pathobiochemistry, University Hospital Magdeburg, Magdeburg, Germany

Received 10 October 2008 ,Accepted 21 January 2009.

References 

  1. Byrne C, Vernon P, Cohen JJ. Effect of age and diagnosis on survival of older patients beginning chronic dialysis. JAMA. 1994;271:34–36
  2. Zager PG, Nikolic J, Brown RH, et al. “U” Curve association of blood pressure and mortality in hemodialysis patients (Medical Directors of Dialysis Clinic, Inc.). Kidney Int. 1998;54:561–569
  3. Fleischmann EH, Bower JD, Salahudeen AK. Are conventional cardiovascular risk factors predictive of two-year mortality in hemodialysis patients?. Clin Nephrol. 2001;56:221–230
  4. McCully KS. Homocysteine and vascular disease. Nat Med. 1996;2:386–389
  5. Refsum H, Nurk E, Smith AD, et al. The Hordaland Homocysteine Study: A community-based study of homocysteine, its determinants, and associations with disease. J Nutr. 2006;136(suppl 6):S1731–S1740
  6. Ganji V, Kafai MR. Third National Health and Nutrition Examination Survey (Demographic, health, lifestyle, and blood vitamin determinants of serum total homocysteine concentrations in the Third National Health and Nutrition Examination Survey, 1988-1994). Am J Clin Nutr. 2003;77:826–833
  7. Robinson K. Renal disease, homocysteine, and cardiovascular complications. Circulation. 2004;109:294–295
  8. Yap S, Boers GH, Wilcken B, et al. Vascular outcome in patients with homocystinuria due to cystathionine beta-synthase deficiency treated chronically: A multicenter observational study. Arterioscler Thromb Vasc Biol. 2001;21:2080–2085
  9. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease (Probable benefits of increasing folic acid intakes). JAMA. 1995;274:1049–1057
  10. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ. 2002;325:1202–1206
  11. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: A meta-analysis. JAMA. 2002;288:2015–2022
  12. Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: A meta-analysis of the randomized trials. Am J Clin Nutr. 2005;82:806–812
  13. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565–575
  14. Bønaa KH, Njølstad I, Ueland PM, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006;354:1578–1588
  15. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567–1577
  16. Suliman ME, Lindholm B, Bárány P, Qureshi AR, Stenvinkel P. Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients. Semin Dial. 2007;20:523–529
  17. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting (Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group). JAMA. 2000;283:2008–2012
  18. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement (Quality of Reporting of Meta-analyses). Lancet. 1999;354:1896–1900
  19. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Systematic reviews of trials and other studies. Health Technol Assess. 1998;2:1–276
  20. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188
  21. Brockwell SE, Gordon IR. A comparison of statistical methods for meta-analysis. Stat Med. 2001;20:825–840
  22. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634
  23. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560
  24. Olkin I. Re: “A critical look at some popular meta-analytic methods.”. Am J Epidemiol. 1994;140:297–299
  25. Song F, Sheldon TA, Sutton AJ, Abrams KR, Jones DR. Methods for exploring heterogeneity in meta-analysis. Eval Health Prof. 2001;24:126–151
  26. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA. 1991;266:93–98
  27. Anan F, Takahashi N, Shimomura T, et al. Hyperhomocysteinemia is a significant risk factor for silent cerebral infarction in patients with chronic renal failure undergoing hemodialysis. Metabolism. 2006;55:656–661
  28. Bachmann J, Tepel M, Raidt H, et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol. 1995;6:121–125
  29. Bostom AG, Shemin D, Lapane KL, et al. Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: A case-control study. Atherosclerosis. 1995;114:93–103
  30. Haraki T, Takegoshi T, Kitoh C, et al. Hyperhomocysteinemia, diabetes mellitus, and carotid atherosclerosis independently increase atherosclerotic vascular disease outcome in Japanese patients with end-stage renal disease. Clin Nephrol. 2001;56:132–139
  31. Kunz K, Petitjean P, Lisri M, et al. Cardiovascular morbidity and endothelial dysfunction in chronic haemodialysis patients: Is homocyst(e)ine the missing link?. Nephrol Dial Transplant. 1999;14:1934–1942
  32. Manns BJ, Burgess ED, Hyndman ME, Parsons HG, Schaefer JP, Scott-Douglas NW. Hyperhomocyst(e)inemia and the prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis. 1999;34:669–677
  33. Nair AP, Nemirovsky D, Kim M, et al. Elevated homocysteine levels in patients with end-stage renal disease. Mt Sinai J Med. 2005;72:365–373
  34. Robinson K, Gupta A, Dennis V, et al. Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation. 1996;94:2743–2748
  35. Suliman ME, Qureshi AR, Barany P, et al. Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int. 2000;57:1727–1735
  36. Vychytil A, Fodinger M, Wolfl G, et al. Major determinants of hyperhomocysteinemia in peritoneal dialysis patients. Kidney Int. 1998;53:1775–1782
  37. Wrone EM, Zehnder JL, Hornberger JM, McCann LM, Coplon NS, Fortmann SP. An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease. Kidney Int. 2001;60:1106–1113
  38. Bayes B, Pastor MC, Bonal J, et al. Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients. Nephrol Dial Transplant. 2003;18:106–112
  39. Bostom AG, Shemin D, Verhoef P, et al. Elevated fasting total plasma homocysteine levels and cardiovascular disease outcomes in maintenance dialysis patients (A prospective study). Arterioscler Thromb Vasc Biol. 1997;17:2554–2558
  40. Buccianti G, Baragetti I, Bamonti F, Furiani S, Dorighet V, Patrosso C. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease. J Nephrol. 2004;17:405–410
  41. Dierkes J, Domröse U, Westphal S, et al. Cardiac troponin T predicts mortality in patients with end-stage renal disease. Circulation. 2000;102:1964–1969
  42. Ducloux D, Bresson-Vautrin C, Kribs M, Abdelfatah A, Chalopin JM. C-Reactive protein and cardiovascular disease in peritoneal dialysis patients. Kidney Int. 2002;62:1417–1422
  43. Ducloux D, Klein A, Kazory A, Devillard N, Chalopin JM. Impact of malnutrition-inflammation on the association between homocysteine and mortality. Kidney Int. 2006;69:331–335
  44. Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol. 2004;15:442–453
  45. London GM, Pannier B, Agharazii M, Guerin AP, Verbeke FH, Marchais SJ. Forearm reactive hyperemia and mortality in end-stage renal disease. Kidney Int. 2004;65:700–704
  46. Mallamaci F, Zoccali C, Tripepi G, et al. Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int. 2002;61:609–614
  47. Moustapha A, Naso A, Nahlawi M, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation. 1998;97:138–141
  48. Sirrs S, Duncan L, Djurdjev O, et al. Homocyst(e)ine and vascular access complications in haemodialysis patients: Insights into a complex metabolic relationship. Nephrol Dial Transplant. 1999;14:738–743
  49. Jamison RL, Hartigan P, Kaufman JS, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial. JAMA. 2007;298:1163–1170
  50. Righetti M, Ferrario GM, Milani S, et al. Effects of folic acid treatment on homocysteine levels and vascular disease in hemodialysis patients. Med Sci Monit. 2003;9:PI19–PI24
  51. Righetti M, Serbelloni P, Milani S, Ferrario G. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients. Blood Purif. 2006;24:379–386
  52. Vianna AC, Mocelin AJ, Matsuo T, et al. Uremic hyperhomocysteinemia: A randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int. 2007;11:210–216
  53. Wrone EM, Hornberger JM, Zehnder JL, McCann LM, Coplon NS, Fortmann SP. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol. 2004;15:420–426
  54. Billion S, Tribout B, Cadet E, et al. Hyperhomocysteinaemia, folate and vitamin B12 in unsupplemented haemodialysis patients: Effect of oral therapy with folic acid and vitamin B12. Nephrol Dial Transplant. 2002;17:455–461
  55. Dierkes J, Domröse U, Ambrosch A, Bosselmann HP, Neumann KH, Luley C. Response of hyperhomocysteinemia to folic acid supplementation in patients with end-stage renal disease. Clin Nephrol. 1999;51:108–115
  56. Sunder-Plassmann G, Födinger M, Buchmayer H, et al. Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: Results of the Vienna multicenter study. J Am Soc Nephrol. 2000;11:1106–1116
  57. Thambyrajah J, Townend JN. Homocysteine and atherothrombosis—Mechanisms for injury. Eur Heart J. 2000;21:967–974
  58. Ingrosso D, Cimmino A, Perna AF, et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet. 2003;361:1693–1699
  59. Pfeiffer CM, Osterloh JD, Kennedy-Stephenson J, et al. Trends in circulating concentrations of total homocysteine among US adolescents and adults: Findings from the 1991-1994 and 1999-2004 National Health and Nutrition Examination Surveys. Clin Chem. 2008;54:801–813
  60. Reis SE, Olson MB, Fried L, et al. Mild renal insufficiency is associated with angiographic coronary artery disease in women. Circulation. 2002;105:2826–2829
  61. Henry RM, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int. 2002;62:1402–1407
  62. Kielstein JT, Salpeter SR, Buckley NS, Cooke JP, Fliser D. Two cardiovascular risk factors in one? (Homocysteine and its relation to glomerular filtration rate. A meta-analysis of 41 studies with 27,000 participants). Kidney Blood Press Res. 2008;31:259–267
  63. Verhoef P, de Groot LC. Dietary determinants of plasma homocysteine concentrations. Semin Vasc Med. 2005;5:110–123
  64. Hoey L, McNulty H, Askin N, et al. Effect of a voluntary food fortification policy on folate, related B vitamin status, and homocysteine in healthy adults. Am J Clin Nutr. 2007;86:1405–1413
  65. Bostom AG, Shemin D, Lapane KL, et al. Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis. 1996;123:193–202

 Originally published online as doi: 10.1053/j.ajkd.2009.01.266 on April 9, 2009.

 J.H. and S.K. contributed equally to this article.

PII: S0272-6386(09)00438-7

doi: 10.1053/j.ajkd.2009.01.266

American Journal of Kidney Diseases
Volume 54, Issue 3 , Pages 478-489 , September 2009

Article Tools

* Image Usage & Resolution